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Ras-GAP SH3 binding protein 1 (G3BP1)A distinctive metabolic trait of tumors is their enforced aerobic glycolysis. This phenotype was ﬁrst reported
by Otto Warburg, who suggested that the increased glucose consumption of cancer cells under aerobic
conditions might result from an impaired bioenergetic activity of their mitochondria. A central player in
deﬁning the bioenergetic activity of the cell is the mitochondrial H+-ATP synthase. The expression of its
catalytic subunit β-F1-ATPase is tightly regulated at post-transcriptional levels during mammalian
development and in the cell cycle. Moreover, the down-regulation of β-F1-ATPase is a hallmark of most
human carcinomas. In this review we summarize our present understanding of the molecular mechanisms
that participate in promoting the “abnormal” aerobic glycolysis of prevalent human carcinomas. The role of
the ATPase Inhibitor Factor 1 (IF1) and of Ras-GAP SH3 binding protein 1 (G3BP1), controlling the activity of
the H+-ATP synthase and the translation of β-F1-ATPase mRNA respectively in cancer cells is emphasized.
Furthermore, we underline the role of mitochondrial dysfunction as a pivotal player of tumorigenesis. This
article is part of a Special Issue entitled: Bioenergetics of Cancer.rgetics of Cancer.
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The term cancer is used to deﬁne a set of heterogeneous diseases in
which abnormal cells divide without control and are able to invade
other tissues. The primary cause of cancer development was initially
attributed to genetic mutations [1]. However, some properties of
cancer cells cannot be explained only by mutations and it has been
accepted that the tumor microenvironment [2] and other epigenetic
events [3] contribute to cancer development and its behavior. A
phenotypic trait of tumors is its peculiar aerobic glycolytic metabo-
lism [4–7], a hallmark that has been recently added to other
alterations acquired by cancer cells in their progression to malignancy
[8]. The enforced aerobic glycolytic metabolism of tumors and cancer
cells was ﬁrst discovered by Otto Warburg many years ago [9,10].
Because the availability of oxygen was known to repress the cellular
rates of glucose consumption (Pasteur effect) [11], Warburg
suggested that the increased aerobic glycolysis observed in carcino-
mas should result from an impaired bioenergetic activity of
mitochondria [9,10]. His hypothesis was heatedly debated [12–14]
and mostly abandoned until the last decade of the previous centurywhen radiation oncologists put back into stage Warburg's postulates
[15–17].
Nowadays, the increased aerobic glycolysis of tumors is out of
question and has been underlined by the widespread clinical
application of tumor imaging by 18F-2-deoxyglucose (FDG) positron
emission tomography (PET), for the diagnosis, staging and follow-up
of cancer patients [15,16]. The boost in aerobic glycolysis is a
requirement for tumorigenesis because it ensures the provision of
the building blocks and reducing power required for the biosynthesis
of the macromolecules that are needed for proliferation [6,18,19]. It
has been argued that some cancer cells growing in vitro depend on
oxidative phosphorylation as the main energy provision pathway
[20–22]. However, transcriptomic, proteomic and functional studies
in prevalent human carcinomas indicate that an enhanced glycolysis
and a repressed bioenergetic activity of mitochondria are required for
tumor progression [23–29]. Moreover, other studies have demon-
strated and summarized the metabolic, molecular and functional
alterations of mitochondria in cancer cells [30–35].
Several mechanisms directly promoting glycolysis, the inhibition
of mitochondrial function or both have been proposed aimed at
explaining the Warburg phenotype of cancer cells and tumors
[4,6,17,19,36–41]. Some authors suggest that the shift to a glycolytic
phenotype results from adaptation to the hypoxic environment where
the tumor grows. Others support that the aforementioned change is
the result of mutations in oncogenes, tumor suppressors and proteins
related to signal transduction pathways (myc, Akt, p53, HIF1-α, and
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involved in cellular energetic metabolism [42–47]. The occurrence of
mutations in mtDNA [48–51] and/or in nucleus-encoded genes
related with the metabolic and bioenergetic function of the organelle
[52–54] has been suggested to be responsible for the metabolic shift
experienced by cancer cells. More recently, and because the cell
division cycle is tightly constraint to aerobic glycolysis [55,56], the
glycolytic phenotype of cancer has been ascribed to the inevitable
metabolic reprogramming experienced by the cells as a result of the
onset of cellular proliferation [4,6,19].
In this review, we will stress the relevance of mitochondrial
dysfunction as a central player of tumorigenesis. We will emphasize
the mechanisms that participate in controlling the content and
activity of the H+-ATP synthase, which is a bottleneck component of
oxidative phosphorylation [57,58] and one of the conﬁrmed targets of
the altered bioenergetic phenotype of human [19,59] and rat [60]
carcinomas. Other aspects of the energetic metabolism of cancer have
been recently summarized elsewhere [4,18,19,40].
2. Localization of the mRNAs of oxidative phosphorylation and the
biogenesis of mitochondria
The bioenergetic phenotype of mammalian cells is adjusted upon
changes in environmental and/or physiological conditions by regulat-
ing the activity of its mitochondria [41,61]. Regulation of mitochon-
drial biogenesis is mainly exerted at the level of transcription in the
nucleus and by replication/transcription in the mitochondrial genome
[62]. Additionally, mechanisms that control the localization [63–65]
and translation [60,66,67] of nucleus-encodedmRNAs ofmitochondria
contribute to deﬁne the bioenergetic phenotype of the cell.
Remarkably, the sorting of nucleus-encoded mRNAs to the vicinity
of mitochondria is a conserved feature in both yeast and mammalian
cells [63,68]. RNA sorting affects the mRNAs that encode core
components of mitochondrial complexes [64,69,70] and involves the
cytoskeleton and cis-acting elements placed in the 3′-untranslated
region (3′UTR) of the mRNAs [64,65,71,72]. The Pumilio (PUF) family
of RNA binding proteins (RNABPs) binds the 3′UTRs and modulates
mRNA expression in a wide variety of eukaryotic species [73]. Puf-
associatedmRNAs display conserved binding sites and usually fall into
the same functionally annotated pathway [74–76]. In this regard,
Puf3p speciﬁcally associates with 256 mRNAs in S. cerevisiae, 90% of
which are nucleus-encodedmitochondrial proteins highly enriched in
mitochondria-bound polysomes [75,77]. Consistently, yeast strains
over-expressing Puf3p exhibit respiratory dysfunction, abnormal
mitochondrial morphology and motility [75,78]. A second class of
224 mitochondria-associated transcripts that lack Puf-binding sites
and whose expression and localization are not affected by PUF3
deletion has been described [77], suggesting the existence of at least
two pathways for mRNA sorting to mitochondria.
The subcellular localization and translation of the mRNA encoding
the catalytic subunit of the mitochondrial H+-ATP synthase (β-F1-
ATPase) has been studied both in yeast and in rat liver cells
[63,66,69,79,80]. In yeast, β-F1-ATPase mRNA (ATP2) is preferentially
sorted to the vicinity of mitochondria by the 3′UTR [71,79,80].
Deletion of the 3′UTR in the ATP2 gene leads to deﬁcient protein
import and reduced ATP synthesis, mtDNA depletion and respiratory
dysfunction [79,80]. Interestingly, ATP2 mRNA was not found as a
Puf3p target and belongs to the aforementioned class of Puf3-
independent mitochondria-localized mRNAs for which the trans-
acting factors remain to be identiﬁed [75,77]. In rat hepatocytes, β-F1-
ATPase mRNA (β-mRNA) is present in a large ~150 nm ribonucleo-
protein (β-RNP) complex preferentially associated to the outer
mitochondrial membrane [63,69] that contains components of the
translational machinery [81]. The assembly and appropriate subcel-
lular localization of β-RNP requires two distal cis-acting elements, one
placed in the open reading frame (ORF) and the other in the 3′UTR[82], and a common set of trans-acting proteins [82]. Recently, similar
ﬁndings have been obtained for the yeast β-mRNA [71], offering a
possiblemechanistic explanation for a co-translational import process
of the β-F1-ATPase precursor into mitochondria, although post-
translational import of the precursor protein has been documented to
operate in in vitro systems [83].
Fig. 1 offers schematic illustrations of two putative pathways by
which the RNP containing β-mRNA (β-RNP) could be sorted
throughout microtubules to the mitochondrial periphery [63]. The
β-mRNA interacts with shuttling RNA binding proteins [84] that
deliver their cargo by speciﬁc interactions with kinesin and dynein
motor proteins. Translation of the mRNA could occur in the tracking
β-RNP up to the sequence in the ORF which acts as a translational
repressor (Fig. 1A) [82]. Anchoring the β-RNP to the mitochondrial
membrane releases the repressor allowing co-translational import of
the encoded protein [85]. The ﬁnding of a translational machinery in
rat liver β-RNPs [81] and the localization-dependent translation of
yeast β-mRNA support this pathway [71]. Alternatively, the β-RNP
might be sorted in a translation repressed state until it reaches the
mitochondrial membrane (Fig. 1B) by the interaction of a repressor
with β-mRNA that impedes the recruitment of the translational
machinery until the β-RNP is anchored to mitochondria.
3. The “altered” bioenergetic phenotype of human tumors
The ﬁnding of an alteration in the expression of the H+-ATP
synthase in rat [60] and many different human [24,27,28,86]
carcinomas concurrent with the induction of glycolytic markers,
strongly supported the original Warburg's hypothesis [59,87]. This
proteomic feature was deﬁned as the “bioenergetic signature of
cancer” [4,24] and has been largely conﬁrmed and extended to
different carcinomas [26,88–92] (see [4] for a recent review). More
recently, we have functionally supported the relevance of Warburg's
postulates after the demonstration that the rates of glucose capture
assessed by FDG-PET imaging inversely correlate with the bioener-
getic signature in lung carcinomas [17]. Moreover, by the generation
of HCT116 colon cancer cell lines expressing different levels of β-F1-
ATPase, to assess the contribution of mitochondrial bioenergetics in
cancer progression [41], we have demonstrated that the activity of
oxidative phosphorylation deﬁnes the rate of glucose utilization by
aerobic glycolysis [41].
Quantitative assays, using high-afﬁnity monoclonal antibodies
against proteins of the “bioenergetic signature” of the cell [93] have
revealed an unanticipated ﬁnding: tumors from different tissues and/
or histological types have the same proteomic signature of energetic
metabolism (β-F1-ATPase/GAPDH ratio), indicating that cancer
abolishes the tissue-speciﬁc differences in the bioenergetic phenotype
of the cell [93]. In other words, energetic metabolism represents an
additional hallmark of the phenotype of the cancer cell [6,8] and a
promising target for the treatment of diverse neoplasias [4,93].
4. Repression of β-F1-ATPase expression in development and
in cancer
The establishment of the bioenergetic function of mitochondria in
the mammalian liver occurs soon after birth [94]. In this process, pre-
existing fetal mitochondria are transformed into functional organelles
[94] by concerted transcriptional and post-transcriptional regulation
of the nuclear and mitochondrial genomes [95–98]. Regarding post-
transcriptional regulation of the metabolic pathways that develop in
liver mitochondria soon after birth, the prenatal storage of transcripts
encoding enzymes of β-oxidation [99], the TCA cycle and its
anaplerosis [99,100], ketone body metabolism [101] and the urea
cycle [102,103] has been described. In particular, themRNAs encoding
nucleus (β-F1-ATPase) and mitochondrial (ATPase 6–8) subunits of
the H+-ATP synthase [95] and of adenine nucleotide translocase [104]
Fig. 1. Sorting the β-RNP to mitochondrial periphery. The nucleus-encoded β-mRNA (blue line) is transcribed in the nucleus and assembled into a large ribonucleoprotein complex
(β-RNP, orange). The cap-structure (black circle) and 3′UTR (red) of the mRNA are shown. After nuclear export, the β-RNP migrates through microtubules (gray line) propelled by
motor proteins (green legs) towards themitochondrial vicinity. A, Translation of themRNA could be initiated in the traveling β-RNP up to a cis-acting element (light blue) in the ORF,
which is targeted by an RNA binding element (RBE) that acts as a translational repressor. The small and large ribosomal subunits are depicted as gray ellipses. When the β-RNP is
anchored to the mitochondrial membrane the pre-sequence of the precursor protein (purple) is recognized by the import machinery, the repressor is released and translation
proceeds concurrent with protein import. B, Translation of β-mRNA is impeded in the migrating β-RNP until it reaches the mitochondria by the inhibitory action of RBE.
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are also stored in the fetal liver. The accumulation of the former two
transcripts is due to an increase in their stability during fetal
development [95,97]. However, these mRNAs are maintained in a
silenced/repressed state until the time of birth, when they become
preferential substrates of their translational machineries [66,95,96,98]
to trigger the functional differentiation of the organelle [94]. The
bioenergetic coupling of the neonatal mitochondria also requires the
intra-mitochondrial accumulation of adenine nucleotides [94] by ATP-
Mg/Pi mitochondrial transporters (SCaMCs) [105,106], contributing
to minimize the high H+-leak of the fetal organelle [107,108].
A conserved translational repressionmechanism for regulating the
expression of β-F1-ATPase in fetal rat liver [66] and in rat hepatomas
[60] has been documented suggesting that it might contribute to the
altered bioenergetic phenotype observed in cancer cells [59,60,87].
Remarkably, the inhibition of mitochondrial biogenesis observed in
As30D and FAO hepatomas occurred, as in the case of fetal
hepatocytes [95,97], in a situation of a concurrent accumulation of
oxidative phosphorylation transcripts mediated by an increase in
their stability [60]. The repression of β-mRNA translation in fetal
hepatocytes and in hepatomas [60] was demonstrated by various
approaches [81,95,96] including the speciﬁc repression of β-mRNA
translation in in vitro assays and the recapitulation of such inhibition
on chimeras that contained the 3′UTR of the transcript [60,66].
Mechanistically, translational regulation could be explained by
differences in the afﬁnity of the mRNA to the translational machinery,
as well as by the action of regulatory proteins and miRNAs that bind
sequence elements within the mRNA for controlling its translation
[66,109–112]. In this regard, we have described that the 3′UTR of rat
β-mRNA is essential for translation of the transcript due to its ability
to interact with components of the translational machinery [66]. The
activity of the 3′UTR in translation is comparable to that previously
described for the sites that promote internal initiation of translation
(IRES) found in viral and other cellular RNAs [113,114]. That is, the 3′
UTR behaves as a translational enhancer both in vitro [66,115] and in
transfected cells [116]. This activity of the 3′UTR is essential for
conferring the appropriate bioenergetic phenotype to daughter cells
during cellular proliferation because it drives the synthesis of β-F1-
ATPase at the G2/M phase of the cycle [67] when cap-dependant
translation is partially inhibited [117].
More recently, we have demonstrated that the 3′UTR of human β-
mRNA is also required for efﬁcient translation of the transcript [118].
Remarkably, we illustrated that the diminished expression of β-F1-
ATPase in prevalent human carcinomas (lung, breast and colon) is
exerted at post-transcriptional levels [118] and also accompanied by a
speciﬁc translation masking event of the β-mRNA [118]. Contrary tothe ﬁndings in rat [60], we observed that human breast and lung
tumor extracts were unable to recapitulate the translational inhibi-
tory effect on RNA chimeras that contained the 3′UTR of human β-
mRNA [118]. These results indicate the existence of mechanistic
differences among mammals for controlling the expression of the
transcript and suggested that in human tissues, in addition to the 3′
UTR, other elements of the transcript are required for its appropriate
translation masking in cancer.
5. Trans-acting factors that regulate β-F1-ATPase mRNA translation
The control of the translation of β-mRNA during development [66]
and in hepatomas [60] involves speciﬁc proteins that bind the rat
transcript. The binding of these proteins is regulated by the energy and
redox state of the cell [119]. It is assumed that the binding of proteins to
the 3′UTR of β-mRNA sterically hinder the initiation of translation
[59,66]. With these ﬁndings in mind, we have pursued the molecular
and functional characterization of the rat and human 3′UTR β-mRNA
interacting proteins. By improving a MS2-based afﬁnity chromatogra-
phy procedure [84], we have identiﬁed that the AU-rich element-
binding protein HuR interacts with the human 3′UTR of β-mRNA [120].
However, functional studies demonstrated that HuR plays an ancillary
role in β-F1-ATPase expression in human cells [120].
As illustrated with RNA chimeras that contain the 3′UTR of rat
β-mRNA, silencing of translation of the rat transcript is due to the
speciﬁc binding of regulatory proteins to the β-mRNA [60,66].
However, the 3′UTR of human β-mRNA does not interact speciﬁcally
with human breast and lung tumor proteins [118]. Moreover,
chimeras containing the 3′UTR of human β-mRNA do not recapitu-
late translational inhibition by tumor extracts [118]. These ﬁndings
forced us to search for the set of RNA binding proteins that interact
with the full-length human β-mRNA by theMS2-basedmethodology
[84]. We have identiﬁed nine RNA binding proteins that interact
in vitrowith β-mRNA [84]. These proteins are involved in transcription
(DHX9, SFPQ, NONO, ILF3, NCL, and NPM), splicing (SFPQ and NONO),
RNA export to the cytoplasm (DHX9, NCL, ILF3 and IMP1), RNA
processing (SFPQ, NONO, NCL and NPM), RNA localization (NCL, NPM,
SFPQ, NONO, G3BP1 and IMP1), RNA stability (IMP1 and G3BP1) and
translation (ILF3, G3BP1, IMP1 and RL8) [84]. Furthermore, DHX9, NCL,
NPM, ILF3, G3BP1 and IMP1 shuttle from the nucleus to the cytoplasm
depending upon environmental conditions [121–124] and form part of
different RNPs that are sorted throughout the cytoplasm by kinesin and
dynein motor proteins [125,126].
We have studied the in vivo interaction of NPM1, IMP1 and G3BP1
with β-mRNA as well as the functional relevance of these proteins in
controlling the expression of β-F1-ATPase [84]. We observed no
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However, the in vivo association of G3BP1 (Ras-GAP SH3 binding
protein 1) with the human β-mRNA has been shown by various
approaches [84]. Moreover, trimolecular ﬂuorescence complementa-
tion assays indicate that G3BP1 interacts with the 3′UTR of β-mRNA
[84] and this interaction speciﬁcally represses mRNA translation by
preventing its recruitment into active polysomes [84]. Therefore, we
suggest that binding of G3BP1 to the 3′UTR of the transcript might
hinder the intrinsic translational enhancing activity of the 3′UTR
[66,118], preventing either 43S recruitment to the mRNA or mRNA
circularization [127] (Fig. 2).
G3BP1 is over-expressed in several tumors and cancer cell lines
[128–130]. Consistent with its role in β-mRNA translation, the over-
expression of G3BP1 in human cells inhibited the synthesis of β-F1-
ATPase without affecting β-mRNA levels [84]. This mechanism of
protein silencing by G3BP1 is at variance with the reported
degradation of c-myc mRNA by the endoribonuclease activity of
G3BP1 [124]. Therefore, our ﬁndings suggest that G3BP1 could play an
essential role in the glycolytic switch that occurs in cellular
transformation, contributing to deﬁne the bioenergetic phenotype
of the cancer cell at the level of translation [84]. Since post-
translational regulatory events inﬂuence the activity of G3BP1
[121,124,131,132] it is reasonable to suggest that these changes
could also participate inmediating β-mRNA translation. The control of
β-F1-ATPase expression in human cancer is mostly exerted at the
level of translation [118]. Translational silencing is usually mediated
by 3′UTR-mediated sequestration of the mRNA into RNPs [109,110]
and/or by miRNA-mediated inhibition of translation [111,112].
Therefore, we cannot exclude the possibility that miRNAs could also
play a role in the regulation of β-mRNA translation both in cancer and
during development.6. Other mechanism that affect the expression/activity of the
H+-ATP synthase in cancer
Recent ﬁndings indicate that promoter hypermethylation of the β-
F1-ATPase gene (ATP5B) limits the expression of the protein in chronic
myeloid leukemia cells, compromising the bioenergetic activity of
mitochondria and contributing to adriamycine resistance [133].
Moreover, we have recently shown that the inhibitor peptide of
the mitochondrial ATPase, called ATPase Inhibitory Factor 1 or IF1
[134–136] is up-regulated in human breast, colon and lung
carcinomas when compared to paired normal tissues [137]. IF1
function has been mostly described as an inhibitor of the hydrolase
activity of the H+-ATP synthase when mitochondrial respiration is
impaired [135,136,138]. In this situation the pH of the mitochondrial
matrix becomes more acidic and IF1 becomes activated and capable
of binding β-F1-ATPase to prevent a useless waste of energyFig. 2. Mechanism of translational repression of β-mRNA by binding of G3BP1 to the 3′U
communication established by the interaction of the scaffolding eIF4F complex (green) and
translation of the transcript at the level of initiation. G3BP1 binding could mask the translat
43S ribosome and/or hinder mRNA circularization.[135,136,139]. More controversial is the role of IF1 as an inhibitor
of the synthase activity [140–144]. Since the binding of IF1 to β-F1-
ATPase is regulated by the energetic state of mitochondria [135,136]
and cancer cells display high mitochondrial membrane potentials
[145], in principle one would expect that IF1 cannot inhibit the H+-
ATP synthase in cancer. However, we have over-expressed IF1 and
its pH-insensitive H49K mutant [135,146] and found that the
expression of these peptides triggers a decrease in the activity of
the H+-ATP synthase, the up-regulation of aerobic glycolysis and a
concurrent increase in the mitochondrial membrane potential,
mimicking the effects of the H+-ATP synthase inhibitor oligomycin
[137]. Conversely, siRNAmediated silencing of IF1 in cells expressing
high levels of IF1 triggers the down-regulation of aerobic glycolysis
and an increase in the activity of the H+-ATP synthase [137].
Therefore, it is reasonable to suggest that the binding of the H+-ATP
synthase by IF1 depends also on the mass-action ratio and, in
situations of increased IF1 expression such as in certain tumors and
cancer cells [137], the protein inhibits both the synthetic and
hydrolytic activities depending upon the energetic state of mito-
chondria and yet uncharacterized post-transcriptional mechanisms
that could regulate the binding activity of IF1 to the H+-ATP
synthase. In agreement with our proposal, recent ﬁndings indicate
that deletion of IEX-1, a stress-inducible gene that apparently targets
IF1 for degradation, results in the inhibition of the ATP synthase
activity in vivo [144]. Therefore, the regulated expression of IF1
provides the cancer cell with an additional mechanism to regulate its
energetic metabolism which has further consequences for tumor
growth [137].7. Energetic metabolism and cancer progression
A perturbation proﬁling approach, to characterize the metabolic
changes that occur during transformation to a cancerous state,
demonstrated that increased energy production by glycolysis in
response to aberrant mitochondrial respiration accompanies the
acquisition of the fully transformed state [147]. In apparent contrast,
it has been reported that transformation of human mesenchymal
stem cells promotes an increase in their dependency on oxidative
phosphorylation [148]. However, when these transformed cells were
implanted into nude mice an increase in glycolysis was observed
accompanied by the down-regulation of genes of the TCA cycle [148].
Likewise, it has been reported that H-RasV12/E1A transformed cells
show an activation of oxidative phosphorylation at an early stage of
transformation [149]. However, as the tumorigenic potential of the
cells increases an enhancement of glycolysis and a diminished activity
of mitochondrial respiration are observed [149]. Consistent with these
ﬁndings, we have recently demonstrated that for in vivo tumor
progression the previous selection of cancer cells with a cellularTR of the transcript. The mRNA is efﬁciently translated in a circular way by the 5′–3′
PABP (yellow). Binding of G3BP1 to the 3′UTR (purple) of β-mRNA (black) inhibits the
ional enhancing activity of the 3′UTR and prevent the interaction of the mRNA with the
Fig. 3. The role of the cellular environment in cancer development. A, Hamster hybrid
cells were derived by fusion of a non-tumorigenic (CHEF/18) nucleus (black) with an
enucleated cytoplasm (orange) of a tumorigenic (CHEF/16) cell or vice versa. Fusions of
a non-tumorigenic cytoplasm (gray) with a tumorigenic nucleus (red) suppress
tumorigenicity [151]. B, Nuclei of medulloblastomas were transferred to enucleated
mice oocytes and the blastocysts implanted into pseudo-pregnant female mice. The
blastocysts derived normal mice embryos (E8.5) [152]. Implantation of the same
medulloblastoma cells into nude mice developed tumors [152].
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repressed is required [41]. The acquisition of this metabolic trait is not
based on a permanent genetic change rather it represents a reversible
feature that results from the metabolic adaptation of the cells to the
milieu where tumor cells develop in vivo [41].
The relevance of the cellular environment in cancer progression is
quite well delineated [150]. In this regard, it has been documented
that nuclei from cancer cells when transplanted into the cytoplasm of
enucleated non-tumorigenic cells (Fig. 3A) [151] or into enucleated
frog or mice oocytes (Fig. 3B) [152–155] are epigenetically repro-
grammed and develop as normal cells (Fig. 3A) or even into normal
tadpoles or mice embryos (Fig. 3B). Contrary to the latter ﬁnding
implantation of the same cancer cells into nude mice resulted in
tumor formation (Fig. 3B). These ﬁndings suggest a relevant tumor
suppressor role for the non-tumorigenic cytoplasms [151–155] within
the context of little chromosomal aberrations of the transplanted
cancer nuclei. In this regard, it has been demonstrated that
pharmacological treatment of cancer cells with dichloracetate
(DCA), that triggers a switch to a mitochondrial-dependent pathway
of energy provision, promotes in vivo tumor regression [41,156–158].
Likewise, induction of mitochondrial oxidative phosphorylation
inhibits cancer growth in mammals [159] and prevents tumorigenic-
ity [160,161]. On the contrary, an impaired mitochondrial respiration
promotes the generation of tumors [162]. Furthermore, mtDNA and
membrane damage enhances tumor progression and metastasis
[163–165]. Overall, these ﬁndings highlight the role of mitochondria
in the epigenetic regulation of tumorigenesis and suggest that
repression of oxidative phosphorylation is a prerequisite for tumor
development [41].
8. The tumor suppressor function of mitochondrial activity
Mitochondria, in addition to their essential role in the production
of biological energy, also play a crucial role in the execution of cell
death [166]. Cellular metabolism is molecularly and functionally
integrated with cell death [167–169]. In this regard, it has been
demonstrated that the execution of cell death requires an efﬁcient
oxidative phosphorylation system [170–173] and speciﬁcally the
molecular components of the H+-ATP synthase [174–177]. In fact, β-
F1-ATPase expression is a predictive marker of the response to
chemotherapy [92,169,178–180]. Consistently, we have demonstrat-
ed that the activity of the H+-ATP synthase is required for the efﬁcient
execution of cell death in cells that depend on oxidative phosphor-
ylation for provision of metabolic energy [169]. The role of the H+-
ATP synthase in the execution of cell death in the former cells is
mediated by the generation of reactive oxygen species (ROS) after
priming the cells with death-inducing agents [41,169], which in turn
promote severe oxidative damage on cellular and mitochondrial
proteins and contribute to effectively swamp the cell into death
[41,169]. Mechanistically, cytotoxic drugs have been suggested to
interfere mitochondrial function, most likely promoting the reverse
functioning of the H+-ATP synthase which results in mitochondrial
hyperpolarization and the subsequent generation of ROS [41,169].
Otherwise, highly glycolytic cells with scarce or no dependence on
oxidative phosphorylation for energy provision are resistant to death
stimuli because they do not produce reactive oxygen species [169].
Recently, using HCT116-derived carcinoma cell lines expressing
different levels of β-F1-ATPase, we have conﬁrmed that it is the
activity of oxidative phosphorylation that drives OXPHOS-geared cell
death in response to the action of chemotherapy [41]. An abrogated
mitochondrial activity contributes to a diminished potential for ROS
signaling in response to 5-ﬂuorouracil treatment [41]. In agreement
with previous ﬁndings [41,178–180], a recent study has further
demonstrated that the down-regulation of β-F1-ATPase expression in
chronic myeloid leukemia leads to adriamycin resistance [133]. All
these ﬁndings have led us to suggest that repression of thebioenergetic function of mitochondria is one of the strategies of the
cancer cell in order to ensure its proliferation by diminishing the
potential to execute ROS-mediated cell death [4].
However, it should be noted that ROS act as a double-edged sword
in cell physiology, being the response of the cell determined by the
intensity and the duration of the ROS signal [181]. As discussed earlier,
an excessive ROS production overwhelming the cellular antioxidant
defense contributes to the execution of cell death. However, if the ROS
signal is transient and tolerated by the antioxidant defense ROS can
signal to pathways that allow proliferation and survival as in the case
of cellular adaptation to hypoxia [182] and the proliferation of cells
when treated with oligomycin [41,183]. Indeed, inhibition of the H+-
ATP synthase by oligomycin treatment or by the over-expression of
IF1 promotes an increase in mitochondrial membrane potential [137]
which is the main cellular source of ROS production [169,184]. The
ﬁnding that many cancer cells over-express IF1 [137] might explain
the “abnormal” high mitochondrial membrane potential observed in
these cells [145]. The over-expression of IF1 in cancer cells and tumors
[137] might thus contribute to trigger a ROS signal compatible with
the expression of genes involved in proliferation and survival and the
perpetuation of the cancer cell [164,185]. However, it should be
mentioned that in some cells mitochondrial membrane potential
could also be maintained by reverse functioning of the H+-ATP
synthase at the expense of ATP generated by glycolysis. In this
situation, inhibition of the H+-ATP synthase will likely contribute to
acceleration of cell death by mechanisms similar to that occurring in
neurons [186] and activated macrophages [187]. In any case, cancer
cells have developed mechanisms to overcome the perils of excessive
ROS signaling as afforded by the over-expression of the uncoupling
protein UCP2 [188] and by the preferential expression of the COX4-2
subunit of the mitochondrial respiratory chain which assures a more
efﬁcient electron transfer to O2 [189].
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Overall, three independent mechanisms can affect the bioener-
getic activity of mitochondria speciﬁcally targeting the H+-ATP
synthase that favor an increase in aerobic glycolysis in the cancer
cell. The ﬁrst one, described in chronic myeloid leukemia, is exerted
by limiting the amount of the mRNA encoding the catalytic β-F1-
ATPase subunit by hypermethylation of the promoter of the ATP5B
gene [133]. A second mechanism, documented in solid breast, lung
and colon carcinomas is mediated by controlling the translation of β-
F1-ATPase mRNA [118] by regulatory RNA binding proteins such as
G3BP1 [84]. A third mechanism involves the inhibition of the activity
of the H+-ATP synthase by increasing the mitochondrial content of its
natural inhibitor IF1 [137]. Irrespective of the mechanism(s) used our
ﬁndings strongly support that the Warburg phenotype of cancer cells
results from an impaired bioenergetic function of mitochondria that is
regulated by metabolic/epigenetic means. Glycolysis is known to
provide an advantageous phenotype that favors cellular proliferation
and invasion [41,190]. Moreover, limiting the activity of the H+-ATP
synthase is also expected to contribute to tumor growth because
oxidative phosphorylation is required for the efﬁcient execution of
cell death. Overall, these studies illustrate the need of further basic
studies aimed at characterizing the complexity of the cellular
response needed for mitochondrial biogenesis in order to understand
the alterations of the mitochondrial proteome that speciﬁcally affect
the content/activity of the H+-ATP synthase in cancer.
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